Leerink analyst Christopher Liu upgraded Nuvalent to Outperform from Market Perform with a price target of $110, up from $69.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvation Bio upgraded to Buy at Jefferies following acquisition of AnHeart
- Nuvalent assumed with a Buy at Guggenheim
- Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
- Nuvalent granted breakthrough therapy designation to NVL-520 by FDA
- Block upgraded, Rivian downgraded: Wall Street’s top analyst calls